Small-Cell Lung Cancer (SCLC) develops in 50% of people with Lambert-Eaton Myasthenic Syndrome (LEMS), and SOX2 has been demonstrated to be an effective method for predicting SCLC in LEMS patients [33]. This evidence concerns the gene SOX2 and small cell lung carcinoma.